Alimta Approval History

Alimta (pemetrexed) is an antifolate antineoplastic agent indicated for the treatment of malignant pleural mesothelioma and locally-advanced and metastatic non-small cell lung cancer (NSCLC).

FDA Approval History for Alimta

DateArticle
Jul  7, 2009Approval Lilly Receives Fourth FDA Approval for Alimta (pemetrexed for injection) as Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer
Sep 29, 2008Approval FDA Grants Lilly's Alimta (Pemetrexed for Injection) Third U.S. Approval
Feb  4, 2004FDA Approves Alimta for use with cisplatin, for the treatment of Malignant Pleural Mesothelioma
Feb  4, 2004Approval FDA Approves Alimta for Malignant Pleural Mesothelioma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web2)